Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis

American Journal of Emergency Medicine

Volumn 36, Issue 10, 2018, Pages 1759-1765

  Zhang, Ying Qi ^a   Zou, Shui Lan ^b   Zhao, Hua ^a   Zhang, Ming Ming ^a   Han, Cai Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b The Central Hospital of Aviation Industry of China   (China)

Author keywords

Ceftriaxone; Community acquired pneumonia; Meta analysis; Randomized controlled trials; Respiratory fluoroquinolones

Indexed keywords

CEFTRIAXONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; BACTERIAL PNEUMONIA; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED INFECTION; COMPARATIVE STUDY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85042677497     PISSN: 07356757     EISSN: 15328171     Source Type: Journal    
DOI: 10.1016/j.ajem.2018.01.079     Document Type: Article

References (32)

1. Thomas, C.P., Ryan, M., Chapman, J.D., Stason, W.B., Tompkins, C.P., Suaya, J.A., et al. Incidence and cost of pneumonia in medicare beneficiaries. Chest 142 (2012), 973–981.
2. Welte, T., Torres, A., Nathwani, D., Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67 (2012), 71–79.
3. Prina, E., Ranzani, O.T., Torres, A., Community-acquired pneumonia. Lancet 386 (2015), 1097–1108.
4. Rello, J., Catalan, M., Diaz, E., Bodi, M., Alvarez, B., Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med. 28 (2002), 1030–1035.
5. Woodhead, M., Welch, C.A., Harrison, D.A., Bellingan, G., Ayres, J.G., Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit. Care, 10(Suppl. 2), 2006 (S1).
6. Leesik, H., Ani, U., Juhani, A., Altraja, A., Microbial pathogens of adult community-acquired pneumonia in Southern Estonia. Medicina (Kaunas) 42 (2006), 384–394.
7. Charles, P.G., Whitby, M., Fuller, A.J., Stirling, R., Wright, A.A., Korman, T.M., et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin. Infect. Dis. 46 (2008), 1513–1521.
8. Cilloniz, C., Ewig, S., Polverino, E., Marcos, M.A., Esquinas, C., Gabarrus, A., et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 66 (2011), 340–346.
9. McCormick, A.W., Whitney, C.G., Farley, M.M., Lynfield, R., Harrison, L.H., Bennett, N.M., et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus Pneumoniae in the United States. Nat. Med. 9 (2003), 424–430.
10. Kim, S.H., Song, J.H., Chung, D.R., Thamlikitkul, V., Yang, Y., Wang, H., et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus Pneumoniae isolates in Asian countries: an Asian network for surveillance of resistant pathogens (ANSORP) study. Antimicrob. Agents Chemother. 56 (2012), 1418–1426.
11. Mandell, L.A., Wunderink, R.G., Anzueto, A., Bartlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44:Suppl. 2 (2007), S27–72.
12. Robertson, M.B., Korman, T.M., Dartnell, J.G., Ioannides-Demos, L.L., Kirsa, S.W., Lord, J.A., et al. Ceftriaxone and cefotaxime use in Victorian hospitals. Med. J. Aust. 176 (2002), 524–529.
13. Leroy, O., Saux, P., Bedos, J.P., Caulin, E., Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128 (2005), 172–183.
14. An, M.M., Zou, Z., Shen, H., Gao, P.H., Cao, Y.B., Jiang, Y.Y., Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 36 (2010), 58–65.
15. Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
16. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21 (2002), 1539–1558.
17. DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control. Clin. Trials 7 (1986), 177–188.
18. Erard, V., Lamy, O., Bochud, P.Y., Bille, J., Cometta, A., Calandra, T., Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 23 (2004), 82–88.
19. Frank, E., Liu, J., Kinasewitz, G., Moran, G.J., Oross, M.P., Olson, W.H., et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin. Ther. 24 (2002), 1292–1308.
20. Katz, E., Larsen, L.S., Fogarty, C.M., Hamed, K., Song, J., Choudhri, S., Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 27 (2004), 395–405.
21. Lee, J.H., Kim, S.W., Kim, J.H., Ryu, Y.J., Chang, J.H., High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study. Clin Drug Investig 32 (2012), 569–576.
22. Welte, T., Petermann, W., Schurmann, D., Bauer, T.T., Reimnitz, P., Group MS, Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy. Clin. Infect. Dis. 41 (2005), 1697–1705.
23. Zervos, M., Mandell, L.A., Vrooman, P.S., Andrews, C.P., McIvor, A., Abdulla, R.H., et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 3 (2004), 329–336.
24. Yi, L., Jian, L.I., Ying, L., Liao, L., Hong, Y.U., Bo, Z., Clinical efficacy of moxifloxacin in the treatment of Mycoplasma pneumonia. Chin. J. Infect. Chemother. 10 (2010), 349–353.
25. Yang, S.G., Zhang, S.H., Efficacy and cost-effectiveness analysis of moxifloxacin hydrochloride and combination of ceftriaxone sodium with azithromycin in the treatment of moderate to severe community acquired pneumonia in elderly patients. Chin. J. New Drugs, 18(10), 2009.
26. Fogarty, C., Siami, G., Kohler, R., File, T., Tennenberg, A., Olson, W., et al. Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin. Infect. Dis. 38 (2004), S16–S23.
27. López-Véjar, C.E., Castellanos-De la Cruz, L., Meraz-Ortega, R., Román-Flores, A., Geuguer-Chávez, L., Pedro-González, A., et al. Eficacia del levofloxacino en el tratamiento de neumonía adquirida en la comunidad. Medicina Interna de México, 29, 2013, 588.
28. Vardakas, K.Z., Siempos, I.I., Grammatikos, A., Athanassa, Z., Korbila, I.P., Falagas, M.E., Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 179 (2008), 1269–1277.
29. Querol-Ribelles, J.M., Tenias, J.M., Querol-Borras, J.M., Labrador, T., Nieto, A., Gonzalez-Granda, D., et al. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int. J. Antimicrob. Agents 25 (2005), 75–83.
30. Fan, H., Liu, S.T., Tong, X., Peng, S.F., Ma, Y., Yan, Z.P., et al. Respiratory fluoroquinolones monotherapy versus β-lactams plus macrolides combination therapy for non-ICU hospitalized community-acquired pneumonia patients: a meta-analysis. Chinese Journal of Evidence-Based Medicine 15 (2015), 824–832.
31. Laopaiboon, M., Panpanich, R., Swa Mya, K., Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst. Rev.(3), 2015 Mar 8, CD001954.
32. FDA, FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm511530, 2016.